Mazen Animal Health

Jennifer Filbey, Ph.D.

CEO

November 7, 2018

First in Class Edible Vaccines

Feed–Through Vaccines For Production Animals

Positive Disruption is our Mission

Producers need:• Increased biosecurity

• Increased production margins

• Decreased antibiotics usage

• Improved disease prevention

Key Unmet Needs in Production Animals

Mazen proposes:• Subunit vaccines (ARS)

• Cost effective

• Replaces antibiotics

• Efficacy demonstrated

Coccidiosis causes $3.5B in annual losses

Mazen & USDA-ARS are Joining Forces to Provide a Cost-

Effective Vaccine Solution to Coccidiosis

• Coccidiosis is currently managed using a cyclical approach of spray

or water-based live vaccines alternated with ionophore antibiotics

and other anti-coccidiosis measures

• We need a safer, more efficacious, easier to use and cost-effective

approach

ARS has sub-unit antigens shown to be

effective against Eimeria infections

• EF-1alpha

• 3-1e/profilin

• Gam82

Mazen can express sub-unit vaccines in

maize grain creating “edible” vaccines

• Can be dosed with feed

• Cost effective

• Can’t replicate

Lillehoj, H. S., Ding, X., Quiroz, M. A., Bevensee, E., and Lillehoj, E. P. (2005) Avian diseases 49, 112-117.

Lin, R.-Q., Lillehoj, H. S., Lee, S. K., Oh, S., Panebra, A., and Lillehoj, E. P. (2017) Veterinary parasitology 243, 79-84.

Jang, S. I., Lillehoj, H. S., Lee, S. H., Lee, K. W., Park, M. S., Cha, S.-R., Lillehoj, E. P., Subramanian, B. M., Sriraman, R., and Srinivasan, V. (2010) Vaccine 28, 2980-2985.

• Over 15 issued and pending patents• Process• Use• Enhanced immunogenicity• Promoters• Ex: 9,944,937

• Patents pending for PEDV and Valley Fever

• Strong IP estate in the U.S.

• Patents pending related to three antigens from USDA-ARS

Clear Defensible & Competitive Advantages

Global Vaccine Market is over $7BRevenue projected to reach $300M by 2026 with US & International

Sales

• Porcine Epidemic Diarrhea

Virus

• Valley fever

• Avian Coccidiosis

(50,000,000)

0

50,000,000

100,000,000

150,000,000

200,000,000

250,000,000

300,000,000

350,000,000

2020 2021 2022 2023 2024 2025 2026

Feline - Rabies

Canine -Rabies

Fish Vaccine -Trout

Feline -Panleuk, Calic,RhinoCanine -Parvo, Dist,HepFish Vaccine -Salmon

Poultry -Coccidiosis

PCV-2 -Swine/Piglet

PEDV -Swine/Piglet

Valley Fever -Canine

EBIT

Mazen Experienced Leadership TeamAnimal Health, Technical & Commercial Expertise

TEAM

Jenny Filbey,

PhD

Founder, CEO

CPA

CFO

John Howard,

PhD

Founder, CSO

Tom Overbay, DVM

Development

CPA

CFO

• World leader in protein

expression in maize grain

• CEO of ABI

• 30 years of biotech

experience

• Entrepreneur focused

on commercialization

of new technologies

• President of NPI

• Nektar, Nobex, Hoechst

• Regulatory, business

development, tech

operations

• Expedite Animal Health

• Finance & corporate

development

• Public & private

company experience

• Animal health, feed

ingredients & production

animal marketing

• Elanco

• Bayer

Candidate

Identified

Candidate

Identified

Kerryann

Kocher

Marketing

Experienced BoardAnimal Health, Technical & Commercial Expertise

TEAM

Kelly

Lechtenberg,

DVM

Terry Speizer,

MBARonan Molloy, JD

• President, Innovation

Stockyard

• Zoetis, Synbiotics,

Primus

• President of Midwest

Veterinary Services &

the Veterinary and

Biomedical Research

Center

• Infectious Disease

Model Specialist

• Food Animal

Production Consultant

• Serial entrepreneur

• Morro View Winery

• Domaine Alfred Winery

• Electec, Flextec

Jenny Filbey,

Ph.D.John Howard,

Ph.D.

• Entrepreneur focused

on commercialization

of new technologies

• President of NPI

• Nektar, Nobex,

Hoechst

• World leader in

protein expression in

maize grain

• CEO of ABI

• 30 years of biotech

experience

PoC Provides Value Creation

Implementation

Antigen

Production

PoC in

target

animal

Master Seed

Working

Seed

EfficacyPre-licensing

SerialsSafety

Key Risk Reduction Step

• Cost effective

• Safer to deliver

• More efficacious

• Global reach

Equity Financing Round is Open Targeting a $20M Raise

Fast to Market for First-in-Class Edible Vaccine

➢10+x multiple on

investment

➢Disrupt animal

disease prevention

globally

11

Jennifer Filbey, Ph.D.

CEO

jfilbey@mazenanimalhealth.com

+1-256-417-8568

www.mazenanimalhealth.com